OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.
Visit go.covermymeds.com/OptumRx to begin using this free service.
Please note: All information below is required to process this request.
Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Humira® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

- ❑ Active ankylosing spondylitis
- ❑ Active psoriatic arthritis (PsA)
- ❑ Moderate to severe chronic plaque psoriasis
- ❑ Moderate to severe hidradenitis suppurativa (e.g., Hurley Stage II or III)
- ❑ Moderately to severely active Crohn's disease
- ❑ Moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)
- ❑ Moderately to severely active rheumatoid arthritis (RA)
- ❑ Moderately to severely active ulcerative colitis
- ❑ Uveitis
- ❑ Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Will Humira be used in combination with a biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]? ❑ **Yes** ❑ **No**

Select if Humira is prescribed by or in consultation with one of the following specialists:

- ❑ Dermatologist
- ❑ Gastroenterologist
- ❑ Ophthalmologist
- ❑ Rheumatologist

For active ankylosing spondylitis, also answer the following:

Has the patient had a trial and failure, contraindication, or intolerance to two non-steroidal anti-inflammatory drugs (NSAIDs)? ❑ **Yes** ❑ **No**

For moderately to severely active Crohn's disease, also answer the following:

Select if the patient has a had trial and failure, contraindication, or intolerance to the following:

- ❑ 6-mercaptopurine
- ❑ Azathioprine (Imuran)
- ❑ Corticosteroid (e.g., prednisone, methylprednisolone)
- ❑ Methotrexate (Rheumatrex, Trexall)

Has the patient had trial and failure (i.e., lost response) or intolerance to Remicade (infliximab)? ❑ **Yes** ❑ **No**

For moderately to severely active polyarticular juvenile idiopathic arthritis (JIA), also answer the following:

Has the patient had a trial and failure, contraindication, or intolerance to Arava (lefunomide) **OR** Rheumatrex/Trexall (methotrexate)? ❑ **Yes** ❑ **No**

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Humira® Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For moderately to severely active rheumatoid arthritis (RA), also answer the following:

Has the patient had a trial and failure, contraindication, or intolerance to one disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate (Rheumatrex/Trexall), leflunomide (Arava), sulfasalazine (Azulfidine)]? ❑ **Yes** ❑ **No**

For moderately to severely active ulcerative colitis, also answer the following:

Select if the patient has had a trial and failure, contraindication, or intolerance to the following:

- ❑ 6-mercaptopurine
- ❑ Aminosalicylate [e.g., Asacol, Pentasa, Rowasa (mesalamine), Dipentum (osalazine), Azulfidine (sulfasalazine)]
- ❑ Azathioprine (Imuran)
- ❑ Corticosteroid (e.g., prednisone, methylprednisolone)

For uveitis, also answer the following:

Does the patient have non-infectious uveitis? ❑ **Yes** ❑ **No**

Select the patient's uveitis classification:

- ❑ Intermediate
- ❑ Panuveitis
- ❑ Posterior

Reauthorization:

If this is a reauthorization request, answer the following questions:

Is there documentation the patient has had a positive clinical response to Humira therapy? ❑ **Yes** ❑ **No**

Will Humira be used in combination with a biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]? ❑ **Yes** ❑ **No**

For ulcerative colitis, also answer the following question:

For patients who initiated Humira therapy within the past 12 weeks: Is there documentation the patient has experienced clinical remission or significant clinical benefit by eight weeks (Day 57) of therapy? ❑ **Yes** ❑ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.
If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**